Buy Rating on Jasper Therapeutics: High Hopes for Briquilimab’s Clinical Trials

H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on JSPR stock, giving a Buy rating yesterday.

Emily Bodnar’s rating is based on the promising developments in the clinical trials of Jasper Therapeutics’ drug candidate, briquilimab. She maintains confidence in the forthcoming positive data from the Phase 1/2 trials for chronic spontaneous urticaria (CSU), expected in the third quarter of 2024. The ongoing enrollment and clearance for new dosing cohorts, coupled with the efficient study design mirroring that of a similar successful Phase 2 trial of barzolvolimab, underpin her optimistic outlook. The potential for briquilimab to offer a superior dosing schedule, particularly if the quarterly dosing proves as effective as the current eight-week schedule, further contributes to the Buy rating.

Furthermore, Bodnar considers the chronic inducible urticaria (CIndU) Phase 1/2 study, albeit small, to be significant enough to potentially demonstrate proof of concept (POC). The study’s design parallels that of barzolvolimab’s Phase 1 trial, which delivered a high response rate. The analyst is keen to observe the durability of briquilimab’s response in comparison to its benchmark, with hopes of achieving a response duration that could justify less frequent dosing. Anticipation of data from both briquilimab in CIndU and further data from barzolvolimab in the second half of 2024 reinforces Bodnar’s recommendation, as positive outcomes could set a solid foundation for advancing briquilimab’s clinical development.

Bodnar covers the Healthcare sector, focusing on stocks such as ACELYRIN, INC., Atossa Therapeutics, and NovoCure. According to TipRanks, Bodnar has an average return of 3.6% and a 36.89% success rate on recommended stocks.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Jasper Therapeutics (JSPR) Company Description:

Amplitude Healthcare Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.